Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections associated with surgical procedures

American Journal of Surgery

Volumn 197, Issue 6, 2009, Pages 791-796

  Wilson, Samuel E ^a   O'Riordan, William ^b   Hopkins, Alan ^c   Friedland, H David ^c   Barriere, Steven L ^c   Kitt, Michael M ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ECMC Department of Surgery   (United States)

^c THERAVANCE INC   (United States)

Author keywords

ATLAS; MRSA; Staphylococcus aureus; Surgical infections

Indexed keywords

TELAVANCIN; VANCOMYCIN;

ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG EFFICACY; GRAM NEGATIVE BACTERIUM; HEADACHE; HUMAN; HYPOKALEMIA; INSOMNIA; MAJOR CLINICAL STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGY; NAUSEA; PHLEBITIS; PRIORITY JOURNAL; PRURITUS; RETROSPECTIVE STUDY; RIGOR; SKIN INFECTION; STATISTICAL SIGNIFICANCE; SURGICAL TECHNIQUE; TREATMENT DURATION; VOMITING;

AGED; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; RETROSPECTIVE STUDIES; SKIN DISEASES, INFECTIOUS; STAPHYLOCOCCAL INFECTIONS; SURGICAL WOUND INFECTION; VANCOMYCIN;

EID: 66149100902     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjsurg.2008.05.012     Document Type: Article

References (16)

1. Nichols R.L. Postoperative infections in the age of drug-resistant Gram-positive bacteria. Am J Med 104 5A (1998) 11S-16S
2. DeFrances C.J., and Podgornik M.N. National Hospital Discharge Survey. Adv Data 2006 (2004) 1-19
3. Cheadle W.G. Risk factors for surgical site infection. Surg Infect (Larchmt) 7 suppl 1 (2006) S7-S11
4. Mangram A.J., Horan T.C., Pearson M.L., et al. Guideline for prevention of surgical site infection, 1999. Hospital Infection Control Practices Advisory Committee. Infect Cont Hosp Epidemiol 20 (1999) 250-280
5. Rennie R.P., Jones R.N., Mutnick A.H., et al. Occurrence and antimicrobial susceptibility patterns of pathogens isolated from skin and soft tissue infections: Report from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 2000). Diagn Microbiol Infect Dis 45 (2003) 287-293
6. Liu C., and Chambers H.F. Staphylococcus aureus with heterogeneous resistance to vancomycin: Epidemiology, clinical significance, and critical assessment of diagnostic methods. Antimicrob Agents Chemother 47 (2003) 3040-3045
7. Centers for Disease Control. Staphylococcus aureus resistant to vancomycin-United States, 2002. JAMA 288 (2002) 824-825
8. Higgins D.L., Chang R., Debabov D.V., et al. Telavancin, a multifunctional lipo glycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 49 (2005) 1127-1134
9. Pace J.L., Krause K., Johnston D., et al. In vitro activity of td-6,424 against Staphylococcus aureus. Antimicrob Agents Chemother 47 (2003) 3602-3604
10. Stryjewski M.E., Graham D.R., Wilson S.E., et al. Telavancin versus vancomycin for the treatment of complicated Gram-positive skin and skin structure infections (ATLAS study). Clin Infect Dis 46 (2008) 1683-1693
11. Wilson S.E., Solomkin J.S., Le V., et al. A severity score for complicated skin and soft tissue infections derived from phase III studies of linezolid. Am J Surg 185 (2003) 369-375
12. Weigelt J., Kaafarani H.M., Itani K.M., et al. Linezolid eradicates MRSA better than vancomycin from surgical-site infections. Am J Surg 188 (2004) 760-766
13. Ellis-Grosse E.J., Babinchak T., Dartois N., et al. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: Results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 41 suppl 5 (2005) S341-S353
14. Arbeit R.D., Maki D., Tally F.P., et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 38 (2004) 1673-1681
15. Jauregui L.E., Babazadeh S., Seltzer E., et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis 41 (2005) 1407-1415
16. Chamberlain R.S., Culshaw D., Donovan B.J., et al. Daptomycin (DAP) use in patients with surgical site infections (SSI) (October 4-7, 2007) Presented at the 45th Annual Meeting of the Infectious Diseases Society of America, San Diego, CA